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Introduction
Natural killer (NK) cells are innate lymphocytes known to
be important players in the early phase of immune defense
against certain microbial infections and tumor growth. They
represent a highly specialized effector population, capable of
mediating cellular cytotoxicity and secreting several
chemokines and cytokines.1-3
Natural killer cells differentiate primarily in the bone mar-
row (BM) from a lymphoid precursor, but final maturation of
NK-cell progenitors can also occur in the periphery, and the
existence of a thymic pathway of NK-cell differentiation has
been described.4,5 Mature NK cells mainly circulate in periph-
eral blood (PB), but are also resident in several lymphoid and
non-lymphoid organs, including the decidua, where they are
the most prominent population in early pregnancy.6 During
maturation, NK cells acquire a number of inhibitory recep-
tors, as well as several activating or co-stimulatory
molecules.7,8 The inhibitory receptors mostly recognize MHC
class I molecules and belong to two distinct groups: the killer
cell immunoglobulin-like receptor (KIR) family, which com-
prises receptors for human leukocyte antigen (HLA)-A, -B, -C
alleles, and C-type lectin receptors, such as CD94/NKG2A,
which binds to non-classical HLA-class I molecule, HLA-E.
Both receptor families include an activating counterpart with
similar specificity, but different ligand affinity. The engage-
ment of these receptors is also important for the acquisition
of functional competence during NK-cell development
through a process defined as NK-cell education or licensing.9,10
The best studied NK-cell activating receptor is the low affini-
ty Fc-g receptor IIIA (CD16) responsible for antibody-depen-
dent cellular cytotoxicity (ADCC).11 Other activating recep-
tors that trigger natural killing, often in combination, include
NKp44, NKp46 and NKp30 Ig-like molecules, collectively
termed natural cytotoxicity receptors (NCR), and DNAM-1
(CD226).12-14 NKG2D is another important activating receptor
that recognizes self proteins up-regulated on stressed or dam-
aged cells.15 The expression of both activating and inhibitory
receptors is highly regulated during NK-cell differentiation
and activation, and some of them are selectively expressed on
distinct NK-cell subsets. Thus, based on receptor repertoire
and expression levels, phenotypically distinct NK-cell popula-
tions have been identified in different tissues, and likely rep-
resent specialized NK-cell subsets capable of mediating differ-
ent functions and endowed with distinct migratory proper-
ties.16,17 Two major subsets of human PB NK cells have been
widely reported: CD56lowCD16high NK cells, which represent
approximately 90% of PB NK cells and are the principal cyto-
toxic NK-cell population, and CD56highCD16+/- cells, which
represent 10% of PB NK cells and more abundantly secrete
immunoregulatory cytokines.16 However, recent evidence
indicates that PB CD56lowCD16neg cells are responsible for nat-
ural cytotoxicity against human leukemia and lymphoma
cells.18
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We phenotypically and functionally characterized a distinct CD56low natural killer cell subset based on CD16
expression levels in bone marrow and peripheral blood of healthy children and pediatric patients with acute lym-
phoblastic leukemia. Our findings demonstrate for the first time that CD56lowCD16low natural killer cells are more
abundant in bone marrow than in peripheral blood and that their frequency is further increased in children with
acute lymphoblastic leukemia. Bone marrow and peripheral blood CD56lowCD16low natural killer cells compared
with CD56lowCD16high natural killer cells express lower levels of killer inhibitory receptors, higher levels of CD27,
CD127, CD122, CD25, but undetectable levels of CD57, suggesting that they have a higher proliferative and dif-
ferentiation potential. Moreover, CD56lowCD16low natural killer cells display higher levels of CXCR4 and unde-
tectable levels of CX3CR1 and can be consistently and rapidly mobilized in peripheral blood in response to
CXCR4 antagonist. Unlike CD56lowCD16high, both bone marrow and peripheral blood CD56lowCD16low natural
killer cells release IFNg following cytokine stimulation, and represent the major cytotoxic natural killer cell popu-
lation against K562 or acute lymphoblastic leukemia target cells. All these data suggest that CD56lowCD16low nat-
ural killer cells are multifunctional cells, and that the presence of hematologic malignancies affects their frequency
and functional ability at both tumor site and in the periphery. 
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ABSTRACT
CD56highCD16+/- NK cells originate from CD34+
hematopoietic precursors through phenotypically distinct
stages, whereas the CD56lowCD16high NK-cell population
can originate from the CD56high subset, upon interaction
with peripheral fibroblasts.19 Moreover, based on the sur-
face density of CD94 and CD62L, functional intermedi-
ates between CD56high and CD56low have also been
described.20-22 This sequential differentiation pathway is
supported by the observation that CD56high NK cells have
longer telomeres than CD56low NK cells, that they predom-
inate in PB earlier after hematopoietic stem cell (HSC)
transplantation, and that they differentiate into CD56low in
humanized mice engrafted with human HSCs in the pres-
ence of human IL-15, a cytokine capable of inducing NK-
cell proliferation and differentiation.20,23-24
Furthermore, it is well established that mature human
CD56low NK cells display marked phenotypic and func-
tional heterogeneity. Indeed, lymph node and tonsil
CD56low NK cells are functionally and phenotypically dif-
ferent from PB CD56low NK cells, in that they are negative
for CD16, KIRs, perforin, and for most NCR that are
acquired after IL-2 stimulation.25,26
Unlike the well-defined stages of BM NK-cell develop-
ment in the mouse, in humans the information on NK-cell
development in BM is rather limited. Indeed, while four
NK-cell developmental intermediates have been
described, both phenotypically and functionally, in human
lymph nodes and tonsils,25,27 no evidence on the effector
functions of the four different NK-cell subsets so far
reported in the BM28 and their relation to the PB counter-
part has been provided. 
In this study, we analyzed the CD56low NK-cell terminal
differentiation in BM and PB of healthy pediatric BM
donors by evaluating the phenotype and the effector func-
tions of NK-cell subsets identified on the basis of the
expression levels of the two major markers of NK-cell lin-
eage CD56 and CD16, namely: CD56highCD16+/-,
CD56lowCD16high and CD56lowCD16low cells. We also
assessed the presence of these NK-cell subsets in BM and
PB of age-matched patients affected by acute lymphoblas-
tic leukemia (ALL) in order to evaluate whether the pres-
ence of lymphoid blasts can shape NK-cell subset distribu-
tion at tumor site and in the periphery. Finally, we investi-
gated the effect of G-CSF administered either alone or in
combination with a CXCR4 antagonist, on the distribu-
tion of PB NK-cell subsets. Our results indicate that
CD56lowCD16low NK cells are a unique subset endowed
with multifunctional activity in BM and PB, and we sug-
gest that they can represent an intermediate differentia-
tion stage between CD56highCD16+/- and CD56lowCD16high
NK cells. Moreover, we also show that the frequency of
distinct NK-cell subsets is affected by the presence of
leukemia cells both at tumor site and in the periphery. 
Methods
Cell source
Peripheral blood and BM cells were obtained from 16 pediatric
healthy donors who donated BM for transplantation at Bambino
Gesù Children’s Hospital, Rome, Italy, and from 19 children with
acute lymphoblastic leukemia (ALL) (5 T-cell and 14 B-cell precur-
sor ALL) at diagnosis (Online Supplementary Table S1). PB mononu-
clear cells (PBMC) were obtained from 9 adult donors given G-CSF
only (12 mg/kg/day for 5 consecutive days) and from 6 donors
receiving G-CSF plus plerixafor (240 mg/kg in single dose) for HSC
mobilization. 
The study was approved by the institutional ethics committees
and informed assent/consent was obtained from donors, patients
and/or their legal guardians.
Multicolor immunofluorescence, cytofluorimetric 
analysis and cell sorting
Freshly isolated PBMC and BM cells were stained using the
appropriate antibody (Ab) combination and subjected to cytofluo-
rimetric analysis. Intracellular staining with appropriate mAb was
performed after fixation with 1% paraformaldehyde and perme-
abilization (0.5% saponin, 1% FCS) (Online Supplementary Table
S1).
Sample acquisition was performed on FACSCantoII (BD
Biosciences, San Jose, CA, USA) flow cytometer, and cytofluori-
metric analysis was performed with FlowJo 9.2.3 (TreeStar,
Ashland, OR, USA).
For cell sorting, PBMCs, freshly isolated by Lymphoprep
(Nycomed AS, Oslo, Norway) gradient centrifugation, were
stained with the appropriate mAb, NK-cell subsets were sorted by
FACSAria (BD Biosciences) and used for cytotoxicity and differen-
tiation assays.
Degranulation assay and IFNg production
Freshly isolated NK-cell subsets from PB or BM were co-cul-
tured with K562 cells or ALL blasts at 1:1 effector/target (E/T) ratio
for 3 h, in the presence of 50 mM monensin (BD Biosciences) for
the last 2 h, and degranulation was assessed by evaluating CD107a
expression.
In some experiments, NK cells were co-cultured with the FcγR+
murine mastocytoma cell line, P815, in the presence of mAbs
directed against the relevant activating NK-cell receptors.
Degranulation was assessed upon 2 h-culture at 37°C.
To assess intracellular IFNg production, cells were incubated
with IL-12 (25 ng/mL) plus IL-15 (50 ng/mL) (PeproTech, London,
UK) at 37°C. After 1 h, 10 mg/mL brefeldin A were added, and cells
were incubated for an additional 12 h. Cells were subsequently
fixed, permeabilized, stained with anti-IFNg-APC, and analyzed
by flow cytometry. To evaluate the ability of NK-cell subsets to
degranulate and produce IFNg FACS-sorted NK-cell subsets were
stimulated with K562 target cells for 6 h, and analyzed for the co-
expression of CD107a and IFNg, as described above.
Cytotoxicity assay
The MHC class I negative human erythroleukemia cell line
K562 was used as target for natural cytotoxicity. In some experi-
ments, the cytotoxic potential of FACS-sorted NK-cell subsets was
evaluated by 51Cr release assay, performed as previously
described.29 
In vitro differentiation assay
FACS-sorted CD56highCD16+/- or CD56lowCD16low or
CD56lowCD16high NK cells were cultured in RPMI 1640 (EuroClone,
Pero, Milano, Italy), supplemented with 10% FCS (EuroClone),
antibiotic, L-glutamine and IL-12 (25 ng/mL) plus IL-15 (25 ng/mL).
NK-cell subsets were characterized at different time points by
immunofluorescence and flow cytometric analysis.
Statistical analysis
t-test or Mann-Whitney U test were used to compare independ-
ent groups; paired t-test or Wilcoxon matched test were used to
compare matched groups. Statistical analyses were performed
using PRISM 6.0 (GraphPad, La Jolla, CA, USA).
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Results
Distribution of NK-cell subsets in BM and PB from
healthy pediatric donors and children with ALL
In order to better characterize the last stages of human
BM NK-cell differentiation, we first analyzed the distribu-
tion of distinct NK-cell subsets in BM and PB of pediatric
healthy BM donors. We dissected the mature CD56+CD3–
NK-cell compartment, based on the expression levels of
CD56 and CD16, into three distinct subsets:
CD56highCD16+/-, the CD56lowCD16high and the
CD56lowCD16low NK cells. According to this classification,
analysis of BM and PB NK cells revealed that the
CD56highCD16+/- NK-cell subset is more abundant in the
BM (12.9±6.4%) than in the PB (9±6%). Similarly, the
CD56lowCD16low NK-cell subset is significantly more abun-
dant in the BM than in the PB, both in frequency (9.6±5%
in the BM vs. 4.7±3% in the PB) and in absolute number.
By contrast, the frequency of CD56lowCD16high NK cells is
higher in PB (85.6±8.4%) than in BM (74.6±12.5%) (Figure
1).
In order to investigate whether the presence of ALL
blasts can affect NK-cell subset distribution, we evaluated
the proportion of the three NK-cell subsets in BM and PB
samples collected from age-matched children with ALL at
diagnosis. In children with ALL, the absolute number of
total NK cells, CD56lowCD16low and CD56highCD16+/- NK-
cell subsets were significantly more abundant in the BM
and PB with respect to healthy donors, whereas no major
differences were observed in the absolute number of
CD56lowCD16high NK cells (Figure 2A and B). 
Collectively, these observations indicate that
CD56lowCD16low NK cells are more abundantly present in
the BM as compared to the PB in physiological conditions,
and that the presence of lymphoid blasts markedly influ-
ences the distribution of distinct NK-cell subsets.
CD56lowCD16low NK cells exhibit a distinct NK-cell 
phenotype
We further characterized the phenotypic profile of
CD56lowCD16low NK cells in the BM and PB from pediatric
healthy donors. First, the expression of different NK-cell
activating receptors was evaluated as percentage of posi-
tive cells (Figure 3) and mean fluorescence intensity (MFI)
(data not shown). We found that CD56lowCD16low NK cells
express intermediate levels of NKG2D with respect to
CD56highCD16+/- and CD56lowCD16high NK-cell subsets, with
no major differences between BM and PB NK cells. With
regard to the expression of the NCR, similar levels of
NKp46 were found on both CD56lowCD16low and on
CD56lowCD16high NK cells both in BM and PB, whereas
higher levels were observed on CD56highCD16+/- NK cells.
By contrast, NKp44, an activating receptor preferentially
expressed on stimulated or tissue resident NK cells, was
present at low levels only in BM CD56highCD16+/- and
CD56lowCD16low NK cells. In addition, we found that
CD56lowCD16low NK cells express lower levels of the co-
stimulatory and adhesion molecule DNAM-1 as compared
to CD56highCD16+/- and CD56lowCD16high NK-cell subsets,
with no major differences observed between BM and PB
compartments (Figure 3A). 
We then evaluated the expression profile of the recep-
tors for the MHC class I molecules associated with NK-cell
education and acquisition of killing capability.30 As expect-
ed, most CD56lowCD16high NK cells express CD158a
(KIR2DL1), CD158b (KIR2DL2), CD158e1 (KIR3DL1),
NKG2A and NKG2C, while CD56highCD16+/- cells are pos-
itive only for the C-type lectin receptor NKG2A, which is
CD56lowCD16low NK cells are multifunctional effectors 
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Figure 1. Natural killer NK-
cell subset distribution in
bone marrow (BM) and
peripheral blood (PB) from
healthy pediatric donors.
(A) Representative dot plots
of NK-cell subsets gated on
CD56+CD3– and dissected
based on the CD56 and
CD16 expression levels.  (B)
Percentage and absolute
cell number/mL of total NK
cells among lymphocytes
and of CD56highCD16+/-,
CD56lowCD16low and
CD56lowCD16high NK-cell sub-
sets in BM (circles) and PB
(squares). BM: n=16; PB:
n=14. **P<0.005;
*P<0.05.
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expressed on this subset at higher levels than on
CD56lowCD16high and CD56lowCD16low NK cells. Notably,
only very few CD56lowCD16low NK cells in PB express
CD158b receptor, most of them being negative for
CD158a, CD158e1 and NKG2C (Figure 3B).
In parallel, we also investigated the expression profile of
several cytokine receptors on PB and BM NK-cell subsets,
namely the alpha(a)-chain of the IL-2R, CD25, and the
beta(b)-chain of IL-2R and IL-15R, CD122. We observed
that CD25 was significantly more expressed on
CD56highCD16+/- and on CD56lowCD16low NK cells than on
CD56lowCD16high NK cells, while CD122 was found pre-
dominantly on BM-derived CD56highCD16+/- NK cells, with
similar but lower levels on both the CD56low NK-cell sub-
sets (Figure 3C). 
In addition, we looked at the expression of the a-chain
of IL-7R, CD127, a receptor preferentially found at higher
levels on pre-pro NK cells and immature NK cells.31 We
found that BM and PB CD56highCD16+/- and
CD56lowCD16low NK-cell subsets express high levels of
CD127, which is undetectable on CD56lowCD16high cells
(Figure 3C).
Based on the pivotal role played by IL-15 on NK-cell
development, homeostasis and activation, and on the role
of other activating cytokines, such as IL-2, in the regula-
tion of NK-cell activation and acquisition of effector func-
tions at different steps of immune responses,32-35 our results
suggest that CD56highCD16+/- and CD56lowCD16low NK cells
more capably survive, proliferate and undergo activation
in response to IL-15 and IL-2. In agreement with these
results, we observed that sorted CD56lowCD16low NK cells
can up-regulate the expression of CD56 after 7-day expo-
sure to IL-15 plus IL-12, thus acquiring a phenotype simi-
lar to that of CD56highCD16+/- NK cells (Figure 4). 
Finally, we investigated the expression of molecules
associated with the maturation/differentiation process,
both on BM and PB NK cells. We found that CD161, a
marker of NK-cell lineage commitment,36 is highly
expressed on BM CD56highCD16+/- and at intermediate lev-
els on CD56lowCD16low and CD56lowCD16high NK cells,
with no major differences between BM and PB compart-
ments. By contrast, the expression of CD57, a marker of
senescent or terminally differentiated NK cells,37,38 was
more abundant on CD56lowCD16high and marginally on
CD56lowCD16low and CD56highCD16+/- NK cells. Moreover,
in both BM and PB compartments, the expression of
CD27, a TNF-R family member which is a marker known
to identify distinct stages of mouse BM NK-cell develop-
ment,39,40 was high on CD56highCD16+/-, lower on
CD56lowCD16low, and undetectable on CD56lowCD16highNK
cells (Figure 3D). Altogether, these results suggest that, like
CD56highCD16+/- NK cells, CD56lowCD16low NK cells repre-
sent a less mature stage than CD56lowCD16high NK cells.
Chemokine and adhesion receptor profile on BM and
PB NK-cell subsets
In order to elucidate the homing properties of BM and
PB NK-cell subsets, we analyzed the expression pattern of
chemokine and adhesion receptors crucial for controlling
lymphocyte trafficking. As shown in Figure 5A, both in
BM and PB, CD56lowCD16low, NK cells have increased
expression levels of the receptor for CXCL12/SDF-1,
CXCR4, while they exhibit only low levels of the receptor
for CXCL10/IP10, CXCR3, and of the receptor for
H. Stabile et al.
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Figure 2. Natural killer (NK)-cell
subset distribution in bone mar-
row (BM) and peripheral blood
(PB) from pediatric leukemic
patients. Percentage and
absolute cell number/μl of total
NK cells among lymphocytes and
of CD56highCD16+/-, CD56lowCD16low
and CD56lowCD16high NK-cell sub-
sets in BM (A, upper panels) and
PB (B, bottom panels) from 19
pediatric leukemic patients
(squares) and 16 healthy pedi-
atric donors (circles).
***P<0.0005; *P<0.05.
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CX3CL1/Fractalkine, CX3CR1. In addition, both in BM
and PB, with respect to CD56lowCD16high NK cells,
CD56lowCD16low NK cells display increased expression lev-
els of the adhesion molecule CD62L, a molecule expressed
on resting, but not on activated, NK cells, and capable of
guiding lymphocyte migration. Collectively, these data
suggest that the CD56lowCD16low NK-cell subset has a pref-
erential tropism for lymph nodes instead of inflamed tis-
sues. Moreover, in accordance with the literature, we
found that CD56lowCD16high NK cells display higher
expression levels of CX3CR1 and lower expression levels
of CD62L. This supports the notion that this NK-cell sub-
set might preferentially migrate to inflamed tissues in
response to Fractalkine.41,42 Both in BM and PB,
CD56highCD16+/- NK cells displayed higher levels of
CD62L, intermediate to low levels of CXCR4 and
CD56lowCD16low NK cells are multifunctional effectors 
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Figure 3. Phenotypic characterization of human bone marrow (BM) and peripheral blood (PB) natural killer (NK)-cell subsets defined by CD56
and CD16 expression levels.  The CD56highCD16+/- (gray histogram), CD56lowCD16low (white histogram) and CD56lowCD16high (black histogram) NK-
cell subsets were gated on CD56+CD3– NK cells and analyzed for the expression of activating (A), MHC class I-specific (B), cytokine (C), and dif-
ferentiation (D) receptors. A representative histogram for the expression of each marker in BM and PB is shown. Dotted histogram represents
isotype-matched control Ig. Mean value+SD of the percentage of positive cells in BM and PB of 5 independent experiments is shown.
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CX3CR1, and undetectable levels of CXCR3, suggesting
that these cells mainly recirculate in the periphery.
In agreement with the higher expression levels of
CXCR4 on CD56lowCD16low NK cells, we observed that
these cells can be mobilized more efficiently when plerix-
afor, a CXCR4 antagonist, is added to G-CSF for HSC
mobilization (Figure 5B).43 These results suggest that
CD56lowCD16low NK cells have a different trafficking
behavior and that, because of the higher expression of
CXCR4, they may be more efficiently retained in BM as
compared to CD56lowCD16high NK cells.
CD56lowCD16low NK cells display higher
degranulating capacity and ability to produce IFN 
within the CD56low NK-cell subset: analysis of BM and
PB of pediatric healthy donors and leukemic patients
To assess the functional properties of BM and PB NK-
cell subsets, we first evaluated their ability to degranulate
upon binding to HLA class-I deficient K562 target cells (in
the absence of exogenously added cytokines).
Interestingly, upon binding to K562 cells, BM and PB
CD56lowCD16low NK cells have the highest degranulation
potential, as evaluated by the percentage of CD107a posi-
tive cells. By contrast, freshly isolated BM or PB
CD56lowCD16high and CD56highCD16+/- NK cells poorly
degranulated upon interaction with K562 cells (Figure 6A).
Similar results were observed at different E:T ratios (data
not shown). These data were further confirmed using sorted
PB NK-cell subsets in a classical 51Cr-release assay against
K562 target (Figure 6B). These results also indicate that the
higher cytotoxic activity attributed to the CD56low NK-cell
population as compared to CD56high NK cells16,17 (Online
Supplementary Figure S1) is mainly confined to the
CD56lowCD16low NK cells. Moreover, by performing a
reverse ADCC assay, we found that CD56lowCD16low NK
cells degranulated in response to stimulation with anti-
NKp46 mAb, used either alone or in combination with
anti-DNAM-1 or anti-NKG2D mAb, similarly to
CD56highCD16+/- NK cells. By contrast, CD56lowCD16high NK
cells, either from BM or PB, expressed lower levels of
CD107a upon triggering of NKp46, DNAM-1 or NKG2D
receptors (Figure 6C and D) independently of the expres-
sion levels of these activating receptors. 
We further assessed the ability to produce IFNg in
response to overnight stimulation with IL-12 plus IL-15.
The results obtained indicate that PB CD56highCD16+/- and
CD56lowCD16low NK-cell subsets are the major producers
of IFNg,  while the percentage of IFNg-producing PB or BM
CD56lowCD16high NK cells is lower (Figure 7A). Moreover,
CD56lowCD16lowand CD56highCD16+/- degranulating NK
cells are also the major IFNg-producing cells upon pre-
treatment with low doses of cytokines followed by bind-
ing to K562 target cells (Figure 7B).
These results indicate that CD56lowCD16low NK cells may
represent a unique subset of NK cells equipped with both
high degranulation capacity and the ability to produce
IFNg. 
We also assayed the degranulation ability of NK-cell
subsets isolated from BM or PB of children with ALL at
diagnosis. We observed that, unlike healthy donors, in
these subjects all NK-cell subsets poorly degranulate in
response to K562 target cells (Figure 8A). Degranulation
assay was performed using as source of effector cells the
PB NK-cell subsets from 2 haploidentical HSC donors, and
as target the leukemic blasts of the corresponding recipi-
ents. Interestingly, we observed that, in both cases, the
CD56lowCD16low NK cells are the only population capable
of degranulation and that they are, therefore, endowed
with the ability to kill leukemic blasts (Figure 8B).
No changes in the expression levels of CD56 and CD16
were observed upon NK-cell binding to target cells (data
not shown).
Discussion
In this study, we identified a subset of CD56low NK cells
characterized by low expression of CD16 that are preva-
lent in the BM both of healthy children and of pediatric
patients with ALL, and that that are endowed with potent
killer and IFNg producing capacity.
The expression of inhibitory receptors belonging to
NKG2 and KIR families reveals that, unlike
CD56lowCD16high NK cells, CD16low NK cells in both BM
and PB display lower levels of KIR that are acquired at late
stages of NK-cell differentiation, thus suggesting that
these cells have not yet completed their development.
Accordingly, the CD56lowCD16low NK-cell subset displays
higher levels of CD27, the expression of which has been
associated with an earlier differentiation stage both in
humans and mice,39,40,44 and with lower levels of the CD57
senescence marker than CD56lowCD16high NK cells.37,38 In
addition, CD56lowCD16low NK cells, differently from
CD56lowCD16highNK cells, express CD25, CD122 and
CD127, the receptor chains for IL-2/IL-15 and IL-7
cytokines, respectively, which play a major role in control-
ling NK-cell development, homeostasis, survival and acti-
vation. This finding further supports the idea that they
have higher proliferative and differentiation potential.  In
addition, in accordance with the higher expression of
CD122, we found that sorted PB CD56lowCD16low NK cells
up-regulate CD56 following 7-day exposure to IL-15 plus
IL-12, as previously reported.45
The analysis of chemokine receptors on BM and PB
CD56lowCD16low NK cells reveals that this subset exhibits
higher expression of CXCR4, whereas CX3CR1 is unde-
H. Stabile et al.
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Figure 4. CD56lowCD16low peripheral blood (PB) natural killer (NK) cells
up-regulate CD56 upon IL-12 plus IL-15 in vitro treatment.
CD56highCD16+/-, CD56lowCD16low and CD56lowCD16high sorted PB NK-cell
subsets were cultured with IL-12 (25 ng/mL) and IL-15 (25 ng/mL)
for seven days. NK-cell phenotypic profile was analyzed on day 3 and
7 of culture. Results of 1 of 3 independent experiments are shown.
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tectable. Again, the expression pattern of these chemokine
receptors is consistent with a more immature phenotype,
since CXCR4 expression was described to decline during
BM NK-cell development in mice,42,46 and CX3CR1 is pre-
dominant on terminally differentiated mouse and human
NK cells.42,47 Notably, higher expression levels of CXCR4
on CD56lowCD16low NK cells, as compared to the other two
NK-cell subsets, paralleled their preferential BM localiza-
tion, and their capacity to be more efficiently mobilized in
response to the combined treatment with G-CSF and pler-
ixafor. 
Our findings also indicate that, among the CD56low NK
cells, the CD16low subset displays the highest degranula-
tion/cytotoxic potential upon binding to K562 target cells
or triggering of activating receptors. In addition, in
response to cytokine stimulation, BM and PB CD16low NK
cells were found to produce IFNg at levels comparable to
the major cytokine producer, the CD56high NK-cell subset.
In the light of the phenotypic profile and the multifunc-
tional ability of the CD56lowCD16low NK cell-subset
described here, we suggest that these cells partially over-
lap with the multifunctional PB NK-cell subset recently
identified based on the high CD62L expression levels21
and with the KIRlow CD94/NKG2Ahigh NK-cell subset
endowed with highly proliferating and IFNg producing
ability upon cytokine stimulation;22 this further substanti-
ates the heterogeneity of their composition. 
There is evidence that CD56lowCD16high NK cells can
undergo downmodulation of CD16 expression after mito-
genic stimulation or co-culture with malignant targets,
resulting in rapid modulation of their activation status and
effector function.48,49 Moreover, CD16 loss is also associat-
ed with downregulation of CD62L expression, this being
attributable to the activation of the metalloprotease
ADAM17.48,49 Therefore, we cannot exclude the possibility
that the CD56lowCD16low NK cells arise from in vivo activa-
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Figure 5. Chemokine receptor
profile on bone marrow (BM)
and peripheral blood (PB)
CD56highCD16+/-, CD56lowCD16low
and CD56lowCD16high natural
killer (NK)-cell subsets and their
distribution in the PB before and
after hematopoietic stem cell
(HSC) mobilization. (A)
Representative histograms of
chemokine receptor expression
on CD56highCD16+/- (gray his-
togram), CD56lowCD16low (white
histogram) and CD56lowCD16high
(black histogram) NK-cell sub-
sets, gated on CD56+CD3–NK
cells. Dotted histogram repre-
sents isotype-matched control
Ig. Mean value+SD of the per-
centage of positive cells and the
mean fluorescence intensity
(MFI) in BM and PB of 5 inde-
pendent experiments is shown.
(B) Percentage and absolute cell
number/mL of total NK cells and
CD56highCD16+/-, CD56lowCD16low
and CD56lowCD16high NK-cell sub-
sets in PB from untreated (cir-
cle), G-CSF (square) or G-CSF
plus Plerixafor (triangle) mobi-
lized donors of allogeneic HSC.
Upper panels show a represen-
tative cytofluorimetric profile of
NK-cell subsets gated on
CD56+CD3– and dissected based
on the CD56 and CD16 expres-
sion levels before and after
mobilization with G-CSF or G-
CSF plus Plerixafor.
****P<0.00005; **P<0.005.
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tion of the CD56lowCD16high subset. However, the
CD56lowCD16low NK cells we described still express higher
levels of CD62L, supporting the idea that these cells likely
represent a distinct NK-cell subset.
Overall, our results suggest that CD56lowCD16low NK
cells represent an intermediate state between CD56high and
CD56lowCD16high NK cells, as has been proposed for the
CD94highCD56low NK-cell subset.22 In addition, based on
their unique functional properties, we suggest that NK-cell
effector functions are acquired either before or independ-
ently from the acquisition of a terminally differentiated
phenotype. Moreover, our data support the notion that
the differentiation of CD56low NK cells may proceed in a
non-linear way, passing through many phenotypically and
functionally distinct intermediate stages.25 The similar phe-
notypic and functional profile we observed in BM and PB
CD56lowCD16low NK cells suggest that they probably repre-
sent a population that can complete its differentiation
pathway either in BM or in other peripheral compart-
ments.
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Figure 6. Cytotoxic activity of peripheral blood (PB) and bone marrow (BM) CD56highCD16+/-, CD56lowCD16low and CD56lowCD16high natural killer
(NK)-cell subsets. BM and PB from healthy donors were co-cultured with K562 and degranulation ability of CD56highCD16+/- (gray histogram),
CD56lowCD16low (white histogram) and CD56lowCD16high (black histogram) NK-cell subsets, gated on CD56+CD3–, was assessed by evaluating the
percentage of CD107a positive cells (A). Mean value+SD of 5 independent experiments is shown. CD56highCD16+/- (black line), CD56lowCD16low
(dark gray line) and CD56lowCD16high (light gray line) sorted NK-cell subsets from PB of healthy donors according to the expression levels of
CD56 and CD16 (inset), was tested against 1x103 51Cr-labeled K562 target cells in a classical NK-cell cytotoxic assay at different E:T ratios. All
experimental groups were analyzed in triplicate (B). NK cells from BM (C) or PB (D) were stimulated with P815 target cells pre-coated with
anti-NKG2D, anti-NKp46, anti-DNAM1 alone or in combination. Degranulation of CD56highCD16+/- (gray histogram), CD56low CD16low (white his-
togram) and CD56lowCD16high (black histogram) NK-cell subsets was assessed by measuring the percentage of CD107a positive cells. Mean
value+SD of 5 independent experiments is shown. 
Figure 7. Effector functions of bone marrow (BM) and peripheral
blood (PB) CD56highCD16+/-, CD56lowCD16low and CD56lowCD16high natu-
ral killer (NK)-cell subsets following cytokine stimulation. (A) Freshly
isolated cells from BM or PB of healthy pediatric donors were stim-
ulated with IL-12 (25 ng/mL) plus IL-15 (50 ng/mL). The percentage
of IFNg positive CD56highCD16+/- (gray histogram), CD56lowCD16low
(white histogram) and CD56lowCD16high (black histogram) NK-cell sub-
sets were assessed by cytofluorimetric analysis. *P<0.05. (B) NK-
cell subsets sorted from PB of healthy donor according to the
expression levels of CD56 and CD16, were stimulated for 18 h with
IL-12 (2 ng/mL) plus IL-15 (5 ng/mL) and then assayed for their abil-
ity to degranulate and to produce IFNγ upon binding to K562 target
cells (E:T ratio=1:1). The percentage of IFNg and CD107a positive
CD56highCD16+/- (gray histogram), CD56lowCD16low (white histogram)
and CD56lowCD16high (black histogram) NK-cell subsets was assessed
by cytofluorimetric analysis. Mean value+SE obtained from 3 inde-
pendent experiments is shown. *P<0.05.  P values were calculated
by comparing stimulated cells with controls.
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Our findings also provide information on the distribu-
tion and functional ability of BM and PB NK-cell subsets in
pediatric patients affected by ALL, the most frequent
childhood neoplasm. CD56lowCD16lowNK cells are present
at higher frequency in both BM and PB, even if these cells
are not fully functional, as previously reported for other
leukemic malignancies.50 Based on their multifunctional
ability, it is conceivable that CD56lowCD16low NK cells
might play a crucial role in controlling tumor growth and
progression. Moreover, our data indicate that
CD56lowD16low NK cells are the only population capable of
anti-leukemic activity and are, therefore, extremely impor-
tant for patients undergoing hematopoietic stem cell trans-
plantation.
We believe that the identification and functional charac-
terization of this NK-cell subset represents an important
advance in understanding human NK-cell development
and may have important implications in clarifying the role
of NK cells under pathological conditions. In addition, in
view of the fact that the CD56lowCD16low NK-cell subset is
highly multifunctional and can be rapidly mobilized from
BM, we propose that it could be the object of preferential
collection and selection for approaches of adoptive
immunotherapy in patients with NK cell-susceptible
hematologic malignancies. Further studies could also clar-
ify the relationship between emergence and persistence of
this subset during post-graft reconstitution and mainte-
nance of remission. 
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Figure 8. Cytolytic activity of CD56lowCD16low natural killer (NK) cells from
acute lymphoblastic leukemia (ALL) patients against K562 and from
haploidentical hematopoietic stem cell (HSC) donors against leukemic
blasts. (A) BM and PB from healthy donors and ALL patients were co-cul-
tured with K562 and degranulation ability of CD56highCD16+/- (gray his-
togram), CD56lowCD16low (white histogram) and CD56lowCD16high (black his-
togram) NK-cell subsets gated on CD56+CD3–, was assessed by evaluat-
ing the percentage of CD107a positive cells. Mean value+SD of 5 healthy
donors, 15 B-ALL and 3 T-ALL patients is shown. (B) CD56highCD16+/- (gray
histogram), CD56lowCD16low (white histogram) and CD56low CD16high (black
histogram) NK-cell subsets from PB of healthy HSC haploidentical donors
(D1 and D2) was tested against recipient 
T-ALL blasts and the percentage of CD107a positive cells was evaluated
as described above.
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